PTCT PTC Therapeutics Inc.

20.27
-0.14  -1%
Previous Close 20.41
Open 20.50
Price To book 4.94
Market Cap 838955962
Shares 41,389,046
Volume 532,782
Short Ratio 12.01
Av. Daily Volume 637,083

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial to commence in 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017. Advisory Committee Meeting September 28, 2017.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. ETFs with exposure to PTC Therapeutics, Inc. : September 20, 2017
  2. Update in Lawsuit for Investors in NASDAQ: PTCT Shares Against PTC Therapeutics, Inc. Announced by Shareholders Foundation
  3. PTC Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PTCT-US : September 18, 2017
  4. Implied Volatility Surging for PTC Therapeutics (PTCT) Stock Options
  5. PTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day
  6. 3 Biotech Stocks That Could Soar in September
  7. PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : August 23, 2017
  8. PTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : August 23, 2017
  9. Edited Transcript of PTCT earnings conference call or presentation 8-Aug-17 8:30pm GMT
  10. PTC Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PTCT-US : August 11, 2017
  11. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  12. PTC Therapeutics reports 2Q loss
  13. PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  14. Investor Network: PTC Therapeutics, Inc. to Host Earnings Call
  15. PTC Therapeutics to Host Conference Call to Discuss Second Quarter Financial Results
  16. PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development
  17. PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet
  18. How These Biotechs Are Dodging Payor Pushback In Muscular Dystrophy
  19. Here's Why PTC Therapeutics, Inc. Popped 45.2% in June
  20. Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference

SEC Filings

  1. 8-K - Current report 171090480
  2. CT ORDER - Confidential treatment order 171059531
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171049607
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016534
  5. 8-K - Current report 171015232
  6. 8-K/A [Amend] - Current report 17945567
  7. 8-K/A [Amend] - Current report 17939868
  8. 8-K - Current report 17938939
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 17916126
  10. 8-K - Current report 17907390